Please provide your email address to receive an email when new articles are posted on . In this Healio Video Perspective from the virtual ARVO meeting, Zdenka Haskova, MD, PhD, explains potential ...
Lucentis (ranibizumab) is a prescription drug that’s used for eye conditions such as macular edema. Lucentis comes as a liquid solution that’s given by injection into the eye. Lucentis is prescribed ...
SAN DIEGO--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the ...
Lucentis is a prescription medication given by injection into the eye and it has side effects. Some Lucentis patients have had detached retinas and serious infections inside the eye. If the eye ...
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
The first-of-its-kind port delivery system with ranibizumab serves as the first wet age-related macular degeneration (AMD) treatment in 15 years to provide an alternative to frequent eye injections.
August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...
Branch retinal vein occlusion (BRVO) has been reported to be the second most common vision-threatening vascular disorder of the retina after diabetic retinopathy worldwide 1,2. BRVO threatens vision, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results